Dynamic Technology Lab Private Ltd Acquires Shares of 11,970 Dyne Therapeutics, Inc. (NASDAQ:DYN)

Dynamic Technology Lab Private Ltd acquired a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) in the 3rd quarter, Holdings Channel.com reports. The fund acquired 11,970 shares of the company’s stock, valued at approximately $430,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Nisa Investment Advisors LLC raised its position in shares of Dyne Therapeutics by 904.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after buying an additional 669 shares in the last quarter. US Bancorp DE raised its position in shares of Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after buying an additional 1,212 shares in the last quarter. Values First Advisors Inc. purchased a new stake in shares of Dyne Therapeutics during the 3rd quarter valued at about $62,000. KBC Group NV raised its position in shares of Dyne Therapeutics by 53.4% during the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after buying an additional 751 shares in the last quarter. Finally, Amalgamated Bank raised its position in shares of Dyne Therapeutics by 39.9% during the 2nd quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock valued at $99,000 after buying an additional 796 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Piper Sandler restated an “overweight” rating and set a $53.00 target price on shares of Dyne Therapeutics in a research report on Monday, September 23rd. JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $43.00 to $35.00 in a research report on Thursday, October 24th. Royal Bank of Canada assumed coverage on shares of Dyne Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $45.00 price objective on the stock. Morgan Stanley increased their price objective on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Finally, Stifel Nicolaus increased their price objective on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. One analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $50.82.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, COO Susanna Gatti High sold 8,976 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total value of $308,864.16. Following the completion of the sale, the chief operating officer now directly owns 131,636 shares in the company, valued at $4,529,594.76. This trade represents a 6.38 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO John Cox bought 32,000 shares of the stock in a transaction on Wednesday, September 4th. The stock was purchased at an average price of $33.04 per share, with a total value of $1,057,280.00. Following the completion of the purchase, the chief executive officer now owns 8,000 shares of the company’s stock, valued at $264,320. This represents a -133.33 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 176,257 shares of company stock worth $6,193,718 over the last three months. Corporate insiders own 20.77% of the company’s stock.

Dyne Therapeutics Price Performance

Shares of DYN stock opened at $30.61 on Friday. The company has a market capitalization of $3.12 billion, a P/E ratio of -8.74 and a beta of 1.10. The company’s 50-day simple moving average is $31.78 and its two-hundred day simple moving average is $35.36. Dyne Therapeutics, Inc. has a one year low of $10.33 and a one year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). On average, research analysts expect that Dyne Therapeutics, Inc. will post -3.45 EPS for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.